Dow rises more than 400 points for record close, Wall Street posts weekly gain: Live updates
The blue-chip Dow gained 426.16 points, or 0.97%, to 44,296.51, a new all-time closing high and its third straight positive ...
Cantech Letter1d
TD launches on VitalHub with a “Buy” rating
As reported by the Globe and Mail, TD analyst David Kwan November 22 launched coverage of VHI with a “Buy” rating and a ...
TD Cowen Raises Vertiv Holdings Co (VRT) Price Target to $141 on AI Momentum and Hyperscale Data Center Demand
We recently compiled a list of the 10 Trending AI Stocks Making Waves Today. In this article, we are going to take a look at ...
Trump's Wall Street head hunt puts spotlight on Apollo
Just a few years after a bruising battle among Apollo's co-founders over succession, the alternative asset manager giant ...
TD Cowen Raises Palo Alto Networks, Inc. (PANW) Price Target to $420, Citing Strong ARR Growth and AI-Driven Innovations
We recently compiled a list of the 10 Trending AI Stocks Making Waves Today. In this article, we are going to take a look at ...
Danimer Scientific price target lowered to $5.50 from $40 at TD Cowen
TD Cowen lowered the firm’s price target on Danimer Scientific (DNMR) to $5.50 from $40 and keeps a Hold rating on the shares. The firm said ...
Investing2d
Fed report suggests bank M&A may remain challenging next year - TD Cowen
Investing.com -- The Federal Reserve’s semi-annual Supervision and Regulation report signals potential headwinds for the mergers and acquisitions (M&A) in 2025, according to TD Cowen. The report found ...
TD Cowen Names Datadog, Inc. (DDOG) as ‘Best Idea for 2025’ with $165 Price Target, Highlighting AI and Cloud Growth
We recently compiled a list of the 15 AI News Shaping Wall Street Today. In this article, we are going to take a look at ...
TD Cowen Remains a Buy on Protagonist Therapeutics (PTGX)
TD Cowen analyst Tara Bancroft maintained a Buy rating on Protagonist Therapeutics (PTGX – Research Report) today and set a price target of ...
1 Wall Street Analyst Thinks Mastercard Stock Is Going to $567. Is It a Buy?
On Friday, TD Cowen's Bryan Bergin slapped a new 12-month price target on Mastercard of $567 per share, well up from his ...
Fintel on MSN4d
TD Cowen Downgrades Spero Therapeutics (SPRO)
Fintel reports that on November 18, 2024, TD Cowen downgraded their outlook for Spero Therapeutics (NasdaqGS:SPRO) from Buy to Hold. Analyst Price Forecast Suggests 574.01% Upside As of October 22, ...